The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
Open accessAbstract
The goal of this review is to systematically address a number of issues raised in the American Society of Clinical Oncology–College of American Pathologists (ASCO-CAP) guidelines on testing for the human epidermal growth factor receptor 2 (HER-2) alteration. A group of investigators who are experienced in the conduct and interpretation of HER-2 assay methods reviewed the ASCO-CAP guidelines and address several areas of the HER-2 testing guidelines with a particular emphasis on biologic and methodologic considerations. Although HER-2 status determined by immunohistochemistry (IHC) and the status determined by fluorescent in situ hybridization (FISH) are significantly correlated, we feel that standard considerations of laboratory testing, including test accuracy, reproducibility, and precision, as well as the current data favor FISH over IHC assay methods for determining HER-2 status. These considerations are clearly important in clinical practice because HER2 amplification is directly linked to protein expression levels in breast cancer. However, this protein is not consistently analyzed in formalin-fixed tissues as a result of variability in fixation methods and times and the impact of fixation on HER-2 protein antigenicity. Conversely, gene amplification and FISH are significantly less dependent on tissue fixation methods, making this assay more reproducible between central and peripheral laboratories than IHC. Moreover, review of the existing data demonstrate that FISH is more strongly correlated with responsiveness to either trastuzumab or lapatinib treatment. Until other methods achieve similar test accuracy, reproducibility, and predictive value, we suggest FISH as the primary HER-2 testing modality for women with breast cancer who are candidates for HER-2–targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citationSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Self-citationTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationLapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Self-citationVogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Self-citationWolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Self-citationLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2894 · Cited by 802
Self-citationPauletti, G., Dandekar, S., Rong, H., Ramos, L., Peng, H., Seshadri, R., & Slamon, D. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.21.3651 · Cited by 670
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H.-M., Bauerfeind, I., Felber, M., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.142 · Cited by 588
Self-citationERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
(1996) · PubMed · Cited by 554
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Paik, S., Bryant, J., Tan-Chiu, E., Romond, E., Hiller, W., Park, K., Brown, A., Yothers, G., Anderson, S., Smith, R., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.852 · Cited by 484
Press, M. F., Hung, G., Godolphin, W. J., & Slamon, D. (1994) · PubMed · Cited by 478
Self-citationJacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., & Schnitt, S. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.1983 · Cited by 457
Goldenberg, M. M. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88288-0 · Cited by 453
HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods
Yaziji, H. (2004) · JAMA · doi:10.1001/jama.291.16.1972 · Cited by 438
Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D., & Jenkins, R. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4744 · Cited by 438
Press, M. F., Pike, M. C., Chazin, V. R., Hung, G., Udove, J. A., Markowicz, M., Danyluk, J., Godolphin, W. J., Sliwkowski, M. X., & Akita, R. W. (1993) · PubMed · Cited by 426
Self-citationDi Leo, A., Gomez, H. L., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M. C., Guerrera, S. F., Koehler, M., Oliva, C., Stein, S. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2578 · Cited by 418
Self-citationPress, M. F., Slamon, D. J., Flom, K. J., Park, J., Zhou, J.-Y., & Bernstein, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.094 · Cited by 391
Self-citationConcordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831
Roche, P. C., Suman, V. J., Jenkins, R. B., Davidson, N. E., Martino, S., Kaufman, P. A., Addo, F. K., Murphy, B., Ingle, J. N., & Perez, E. A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.855 · Cited by 390
Mass, R. D., Press, M. F., Anderson, S., Cobleigh, M. A., Vogel, C. L., Dybdal, N., Leiberman, G., & Slamon, D. J. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.026 · Cited by 359
Self-citationLapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
(2007) · New England Journal of Medicine · doi:10.1056/nejmx070016 · Cited by 350
Press, M. F., Sauter, G., Bernstein, L., Villalobos, I. E., Mirlacher, M., Zhou, J.-Y., Wardeh, R., Li, Y.-T., Guzman, R., Ma, Y., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0636 · Cited by 311
Self-citationJacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., & Schnitt, S. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.1974 · Cited by 302
Baselga, J. M., Tripathy, D., Mendelsohn, J., Baughman, S. A., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J. L., et al. (1999) · PubMed · Cited by 300
Evaluating HER2 amplification and overexpression in breast cancer
Bartlett, J. M. S., Going, J. J., Mallon, E. A., Watters, A. D., Reeves, J. R., Stanton, P., Richmond, J., Donald, B., Ferrier, R., & Cooke, T. G. (2001) · The Journal of Pathology · doi:10.1002/path.971 · Cited by 242
Self-citationDowsett, M., Bartlett, J., Ellis, I., Salter, J., Hills, M., Mallon, E., Watters, A., Cooke, T., Paish, C., Wencyk, P., et al. (2003) · The Journal of Pathology · doi:10.1002/path.1313 · Cited by 231
Self-citationHER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Elkin, E. B., Weinstein, M. C., Winer, E. P., Kuntz, K. M., Schnitt, S. J., & Weeks, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.158 · Cited by 230
Dybdal, N., Leiberman, G., Anderson, S., McCune, B., Bajamonde, A., Cohen, R. L., Mass, R. D., Sanders, C., & Press, M. F. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-6275-8 · Cited by 216
Self-citationPerez, E. A., Roche, P. C., Jenkins, R. B., Reynolds, C. A., Halling, K. C., Ingle, J. N., & Wold, L. E. (2002) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62329-x · Cited by 214
Best Practice No 176: Updated recommendations for HER2 testing in the UK
Ellis, I. O., Bartlett, J., Dowsett, M., Humphreys, S., Jasani, B., Miller, K., Pinder, S. E., Rhodes, A., & Walker, R. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.007724 · Cited by 177
Self-citationPress, M. F., Finn, R. S., Cameron, D., Di Leo, A., Geyer, C. E., Villalobos, I. E., Santiago, A., Guzman, R., Gasparyan, A., Ma, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1056 · Cited by 171
Self-citationIncreased HER2 With U.S. Food and Drug Administration-Approved Antibody
Roche, P. C., & Ingle, J. N. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.434 · Cited by 147
Automated Screening for Genomic Imbalances using Matrix-Based Comparative Genomic Hybridization
Weßendorf, S., Fritz, B., Wrobel, G., Neßling, M., Lampel, S., Göttel, D., Küpper, M., Joos, S., Hopman, T., Kokocinski, F., et al. (2002) · Laboratory Investigation · doi:10.1038/labinvest.3780394 · Cited by 97
Studies of the HER-2/neu Proto-oncogene in Human Breast Cancer
Slamon, D. J. (1990) · Cancer Investigation · doi:10.3109/07357909009017573 · Cited by 91
Self-citationClinical Laboratory Assays for HER-2/ neu Amplification and Overexpression
(2002) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2002-126-0803-clafhn · Cited by 74
Ciampa, A., Xu, B., Ayata, G., Baiyee, D., Wallace, J., Wertheimer, M., Edmiston, K. L., & Khan, A. A. (2006) · Applied immunohistochemistry & molecular morphology · doi:10.1097/01.pai.0000150516.75567.13 · Cited by 41
29th Annual San Antonio Breast Cancer Symposium 2006
(2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9567-y · Cited by 31
Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D. W., & Jenkins, R. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.567 · Cited by 20
Rossi, E., Ubiali, A., Cadei, M., Balzarini, P., Valagussa, E., Lucini, L., Alpi, F., Galletti, A. M. R., Fontana, L., Tedoldi, C., et al. (2006) · Applied immunohistochemistry & molecular morphology · doi:10.1097/01.pai.0000155795.41654.b1 · Cited by 15
Sensitization of chemotherapy by anti-HER
Kataoka, A., Ishida, M., Murakami, S., & Ohno, S. (2004) · Breast Cancer · doi:10.1007/bf02968288 · Cited by 9
Cited by
HER2: Biology, Detection, and Clinical Implications
Gutierrez, C., & Schiff, R. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0454-rar.1 · Cited by 652
HER2 expression status in diverse cancers: review of results from 37,992 patients
Yan, M., Schwaederle, M., Arguello, D., Millis, S. Z., Gatalica, Z., & Kurzrock, R. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9552-6 · Cited by 483
Niikura, N., Liu, J., Hayashi, N., Mittendorf, E. A., Gong, Y., Palla, S. L., Tokuda, Y., Gonzalez-Angulo, A. M., Hortobagyi, G. N., & Ueno, N. T. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8889 · Cited by 410
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Wang, J., & Xu, B. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0069-2 · Cited by 393
Mittendorf, E. A., Wu, Y., Scaltriti, M., Meric-Bernstam, F., Hunt, K. K., Dawood, S., Esteva, F. J., Buzdar, A. U., Chen, H., Eksambi, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1735 · Cited by 330
“480 Age at diagnosis, y Median (range) 50 (21-81) 48 (25-74) 52 (21-81) 0.”
Background
Metadata
- Authors
- Sauter, G., Lee, J., Bartlett, J. M. S., Slamon, D. J., & Press, M. F.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-03-10
- Volume
- 27
- Issue
- 8
- Pages
- 1323-1333
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2138523273
- Cited by
- 509
- References
- 49
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.